VTRS logo

VTRSViatris Inc

$16.32
$0.54
(3.42%)
Today
Closed $16.31
$0.01
(0.06%)
After Hours
Updated: 07:24 PM EDT
EarningsAug 6
Mkt Cap$18.36B
Vol11.08M
46

Neutral Sentiment

How do you feel about VTRS?

News
all
press releases
Is Amneal a Buy Before Rytary Generic Erosion?
AMRX faces Rytary generic pressure in 2026, but growth in generics, injectables, biosimilars, and higher profitability targets could support its outlook.
Zacks
News Placeholder
More News
News Placeholder
3 Generic Drug Stocks to Watch as New Growth Drivers Emerge
Sandoz, Teva and Viatris target biosimilars, complex generics and specialty drugs as new growth drivers reshape the Medical - Generic Drugs industry.
Zacks
News Placeholder
Here's Why Viatris (VTRS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
News Placeholder
Analyst Report: Viatris Inc
Analyst Report: Viatris Inc...
Yahoo! Finance: News
News Placeholder
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy
VTRS' fast-acting meloxicam NDA enters FDA review as a non-opioid acute pain therapy, with a decision expected by Dec. 27, 2026.
Zacks
News Placeholder
Here's Why Viatris (VTRS) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
News Placeholder
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for...
PR Newswire
News Placeholder
Why Viatris (VTRS) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
News Placeholder
Why Viatris (VTRS) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
News Placeholder
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
Theravance Q1 earnings top estimates as collaboration revenues grow, while restructuring and cost cuts aim to drive $60-$70M annualized cash flow.
Zacks
<
1
2
...
>

Advertisement|Remove ads.